Background/Aims: Stromal cell-derived factor-1 (SDF-1) has been shown to mediate a broad range of biological processes via CXCR4, once regarded as its only receptor. CXCR7 is a recently identified receptor for SDF-1. This study aimed to investigate whether the CXCR7/CXCR4/SDF-1 axis is involved in choroidal neovascularization (CNV) formation in an in vitro hypoxic model. Methods: CXCR7 siRNA and/or CXCR4 siRNA was transfected into a hypoxic model of the choroid-retinal endothelial RF/6A cell line. CCK-8 analysis, transwell migration analysis, annexin V-FITC and propidium iodide staining, and Matrigel tube formation analysis were performed to investigate the role of CXCR4 and CXCR7 in SDF-1-induced proliferation, migration, survival and tube formation of RF/6A cells. Results: CXCR4, but not CXCR7, mediates SDF-1-induced RF/6A cell migration and proliferation under hypoxic conditions, whereas CXCR7 was exclusively involved in RF/6A cell survival. In addition, CXCR7 and CXCR4 acted together to regulate RF/6A cell tube formation. Conclusion: The CXCR7/CXCR4/SDF-1 axis plays an important role in the formation of CNV, and may become a novel target for the treatment of CNV-associated diseases.

1.
Friedman DS, O'Colmain BJ, Munoz B, et al: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
2.
Hou HY, Liang HL, Wang YS: Bone marrow-derived cells in neovascular age-related macular degeneration: contribution and potential application. Ophthalmic Res 2011;45:1-4.
3.
Dong X, Wang YS, Dou GR, et al: Influence of Dll4 via HIF-1α-VEGF signaling on the angiogenesis of choroidal neovascularization under hypoxic conditions. PLoS One 2011;6:e18481.
4.
Burns JM, Summers BC, Wang Y, et al: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-2213.
5.
Hung SC, Pochampally RR, Hsu SC, et al: Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007;2:e416.
6.
Balabanian K, Lagane B, Infantino S, et al: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280:35760-35766.
7.
Liu H, Xue W, Ge G, et al: Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. Biochem Biophys Res Commun 2010;401:509-515.
8.
Wang X, Li C, Chen C, et al: Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1α activation. Biochem Biophys Res Commun 2008;371:283-288.
9.
Hartmann TN, Grabovsky V, Pasvolsky R, et al: A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008;84:1130-1140.
10.
Boldajipour B, Mahabaleshwar H, Kardash E, et al: Control of chemokine-guided cell migration by ligand sequestration. Cell 2008;132:463-473.
11.
Shao H, Tan Y, Eton D, et al: Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells 2008;26:1376-1384.
12.
Grossniklaus HE, Green WR: Choroidal neovascularization. Am J Ophthalmol 2004;137:496-503.
13.
Guerreiro R, Santos-Costa Q, Azevedo-Pereira JM: The chemokines and their receptors: characteristics and physiological functions. Acta Med Port Suppl 2011;4:967-976.
14.
Yan H, Cui J, Wang Y, Yu Y: Comparison of the effects between intravitreal and periocular injections of adenoviral vectored pigment epithelium-derived factor on suppressing choroidal neovascularization in rats. Ophthalmic Res 2012;49:81-89.
15.
Yan L, Wu W, Wang Z, Li C, Lu X, Duan H, Zhou J, Wang X, Wan P, Song Y, Tang J, Han Y: Comparative study of the effects of recombinant human epidermal growth factor and basic fibroblast growth factor on corneal epithelial wound healing and neovascularization in vivo and in vitro. Ophthalmic Res 2012;49:150-160.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.